Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
The latest upgraded Tele Clinic is Artificial Intelligence (AI) - driven to provide healthcare facilities in far flung areas of the region, where such facilities are either not available or inadequately available
Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Comprehensive clinical development programs being initiated for each investigational candidate
The company has received five final approvals
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Subscribe To Our Newsletter & Stay Updated
